Nitrobenzyl Cages for Prodrug Design

Prodrugs are compounds designed to release their active drug component in a spatiotemporally controlled manner enhancing the drug’s selectivity and improving its pharmacokinetic profile. Medicinal chemists have developed several prodrugs that utilize the hypoxia-induced reduction of nitro groups to release their active ingredients specifically within the reductive environment of cancer cells. One notable example is tarloxotinib, a tyrosine kinase inhibitor that has been evaluated in several Phase 2 clinical trials. This prodrug mechanism is conceptually similar to that of photo-caged compounds, which release their active components upon irradiation, enabling precision therapy. Discover our collection of cage-installing reagents for innovative prodrug design!